Sintilimab
- Generic Name
- Sintilimab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 2072873-06-2
- Unique Ingredient Identifier
- 8FU7FQ8UPK
- Associated Conditions
- -
- Associated Therapies
- -
Chemoradiotherapy With or Without Sintilimab in Limited-stage SCLC
- Conditions
- Interventions
- First Posted Date
- 2019-12-06
- Last Posted Date
- 2019-12-06
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 140
- Registration Number
- NCT04189094
Sintilimab in Combination With R-CHOP in Patients With Treatment-naive EBV-positive DLBCL, NOS
- First Posted Date
- 2019-11-29
- Last Posted Date
- 2019-11-29
- Target Recruit Count
- 55
- Registration Number
- NCT04181489
- Locations
- 🇨🇳
The first Affiliated Hospital Of Nanjing Medical University(JiangSu Province Hospital), NanJing, Jiangsu, China
🇨🇳Drum tower hospital, Nanjing, Jiangsu, China
🇨🇳Xuzhou Central Hospital, Xuzhou, Jiangsu, China
Phase II Study to Evaluate the Efficacy and Safety of Fruquintinib Plus Sintilimab as Third-line Therapy for Colorectal Cancer
- First Posted Date
- 2019-11-26
- Last Posted Date
- 2019-11-26
- Lead Sponsor
- Chinese PLA General Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT04179084
- Locations
- 🇨🇳
China PLAGH, Beijing, China
Anti-PD-1 Antibody Plus DEB-TACE for BCLC Stage A/B HCC
- First Posted Date
- 2019-11-22
- Last Posted Date
- 2022-06-09
- Lead Sponsor
- Zhejiang University
- Target Recruit Count
- 61
- Registration Number
- NCT04174781
- Locations
- 🇨🇳
the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
SinTilimab After Radiation (STAR Study)
- First Posted Date
- 2019-11-19
- Last Posted Date
- 2019-11-19
- Lead Sponsor
- Peking Union Medical College Hospital
- Target Recruit Count
- 37
- Registration Number
- NCT04167657
- Locations
- 🇨🇳
Department of Respiratory Medicine, Peking Union Medical College Hospita, Beijing, Beijing, China
Combination of Sintilimab and Stereotactic Body Radiotherapy in Hepatocellular Carcinoma (ISBRT01)
- Conditions
- Interventions
- First Posted Date
- 2019-11-18
- Last Posted Date
- 2021-03-23
- Lead Sponsor
- Mian XI
- Target Recruit Count
- 116
- Registration Number
- NCT04167293
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
Sintilimab in FH-deficient Renal Cell Carcinoma
- First Posted Date
- 2019-10-31
- Last Posted Date
- 2020-05-12
- Lead Sponsor
- West China Hospital
- Target Recruit Count
- 37
- Registration Number
- NCT04146831
Sintilimab and Nab-paclitaxel in Second-line Treatment of Advanced Gastric or Gastro-oesophageal Junction Adenocarcinoma
- Conditions
- Interventions
- First Posted Date
- 2019-10-25
- Last Posted Date
- 2022-03-11
- Lead Sponsor
- Chinese Academy of Medical Sciences
- Target Recruit Count
- 60
- Registration Number
- NCT04140318
- Locations
- 🇨🇳
Chinese Academy of Medical Sciences, Beijing, China
SBRT in Combination With Sintilimab and GM-CSF for the Treatment of Advanced NSCLC
- First Posted Date
- 2019-09-26
- Last Posted Date
- 2019-09-26
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 63
- Registration Number
- NCT04106180
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China
Safety and Efficacy of Radiotherapy Plus Sintilimab for HCC With Portal Vein Tumor Thrombosis
- Conditions
- Interventions
- First Posted Date
- 2019-09-26
- Last Posted Date
- 2020-07-07
- Lead Sponsor
- Beijing Tsinghua Chang Gung Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT04104074
- Locations
- 🇨🇳
Beijing Tsinghua Changgung Hospital, Beijing, Beijing, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.